<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01475513</url>
  </required_header>
  <id_info>
    <org_study_id>HM13769</org_study_id>
    <nct_id>NCT01475513</nct_id>
  </id_info>
  <brief_title>Oral Contraceptives, Insulin Resistance and Cardiovascular Risk Profile in Pre-Menopausal Women</brief_title>
  <official_title>Oral Contraceptives, Insulin Resistance and Cardiovascular Risk Profile in Pre-Menopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Birth control pills are the most commonly used method of birth control. The purpose of this
      research study is to examine whether birth control pills change heart disease risk and how
      the body handles blood sugar when given to different women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The oral contraceptive pill is the most commonly used birth control method. It is debated
      whether the birth control pill affects how the body handles insulin and sugar, or whether the
      pill changes heart disease risk. The goal of this study is to evaluate whether certain
      factors, such as how the body processes hormones, and demographic factors (e.g. body weight
      and race), influence how the pill affects the handling of insulin and sugar, and heart
      health.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Estrogen Metabolites at 6 months</measure>
    <time_frame>Baseline, 3 months, 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Insulin Sensitivity at 6 months</measure>
    <time_frame>baseline, 3 months, 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Flow-mediated Vasodilatation at 6 months</measure>
    <time_frame>baseline, 3 months, 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Carotid Intima Media Thickness at 6 months</measure>
    <time_frame>baseline, 3 months, 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Urinary Estrogen Metabolites at 6 months</measure>
    <time_frame>Baseline, 3 months, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Acute Insulin Response to Glucose at 6 months</measure>
    <time_frame>Baseline, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Glucose Effectiveness in 6 months</measure>
    <time_frame>Baseline, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Disposition Index at 6 months</measure>
    <time_frame>Baseline, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Fasting Insulin at 6 months</measure>
    <time_frame>Baseline, 3 months, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Fasting Glucose at 6 months</measure>
    <time_frame>Baseline, 3 monhts, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Areas-under-the-curve for Insulin at 6 months</measure>
    <time_frame>Baselines, 3 months, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Areas-under-the-curve for Glucose at 6 months</measure>
    <time_frame>Baseline, 3 months, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Cardiovascular Markers (hsCRP, MCP-1, ICAM-1, V-CAM-1, PAI-1, tPA, RBP4, adiponectin, MMP, MPO) at 6 months</measure>
    <time_frame>Baseline, 3 months, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Blood Pressure at 6 months</measure>
    <time_frame>Baseline, 3 months, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Fasting Lipid Panel at 6 months</measure>
    <time_frame>Baseline, 3 months, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Body Mass Index in 6 months</measure>
    <time_frame>Baseline, 3 months, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Waist-to-hip Ratio at 6 months</measure>
    <time_frame>Baseline, 3 months, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin A1c</measure>
    <time_frame>Baseline, 3 months, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum free fatty acids</measure>
    <time_frame>baseline, 3 months, 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Insulin Sensitivity</condition>
  <condition>Cardiovascular Risk</condition>
  <condition>Perimenopausal Disorder</condition>
  <arm_group>
    <arm_group_label>African-American women</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>African-American women</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Caucasian women</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Caucasian women</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ortho CyclenÂ®</intervention_name>
    <description>Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) will be taken as one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.</description>
    <arm_group_label>African-American women</arm_group_label>
    <arm_group_label>Caucasian women</arm_group_label>
    <other_name>Orthocyclen</other_name>
    <other_name>Sprintec</other_name>
    <other_name>Previfem</other_name>
    <other_name>MonoNessa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Premenopausal, regular-cycling women 18-35 years

          -  Either African-American or Caucasian (African-American and Caucasian women will be
             BMI-matched)

          -  non-smoker.

        Exclusion Criteria:

          -  Diabetes

          -  Clinically significant pulmonary, cardiac, renal, hepatic, neurologic, psychiatric,
             infectious, and malignant disease

          -  Contraindications to oral contraceptive use (history of blood clots, heart attacks or
             stroke, vascular disease, coagulopathy, prolonged immobilization, breast cancer,
             migraine head-aches, major surgery within past 6 months, blood pressure &gt;160/100 mmHg,
             pregnancy or lactation)

          -  Use of hormonal contraceptives, glucose-lowering medications, anti-hyperlipidemic,
             anti-hypertensive or other vasoactive drugs within previous 3 months
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kai Cheang, Pharm. D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia Commonwealth University Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298-0111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2011</study_first_submitted>
  <study_first_submitted_qc>November 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2011</study_first_posted>
  <last_update_submitted>February 12, 2018</last_update_submitted>
  <last_update_submitted_qc>February 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>oral contraceptive</keyword>
  <keyword>birth control pill</keyword>
  <keyword>women</keyword>
  <keyword>healthy volunteer</keyword>
  <keyword>insulin sensitivity</keyword>
  <keyword>insulin resistance</keyword>
  <keyword>cardiovascular risk factors</keyword>
  <keyword>endothelial function</keyword>
  <keyword>estrogen metabolism</keyword>
  <keyword>racial difference</keyword>
  <keyword>glucose intolerance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Moxifloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

